BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 14, 2018
View Archived Issues
XW Laboratories initiates phase I study of XW-10172 for narcolepsy
Read More
Sosei regains rights to CGRP antagonist programs from Teva
Read More
Identification of novel locus for idiopathic dilated cardiomyopathy in African Americans
Read More
MB-66 vaginal film shows HIV, HSV neutralizing activity in phase I study
Read More
Patient enrollment begins in phase III study of favipiravir for thrombocytopenia syndrome
Read More
Reduced adverse effect potential demonstrated with Mebias Discovery's mu-opioid receptor agonists
Read More
Researchers present data on mRNA-based vaccine for HIV-1 infection
Read More
AbbVie gains rights to discovery programs from X-Chem
Read More
Bellicum Pharmaceuticals reports encouraging interim data from clinical trial of BPX-501
Read More
Shionogi launches Xofluza in Japan
Read More
Ideaya Biosciences, CRUK enter partnership to develop PARG inhibitors
Read More
Intra-Cellular Therapies plans rolling NDA submission for lumateperone
Read More
AbCellera Biologics receives DARPA contract for rapid countermeasures against viral outbreaks
Read More
Ardelyx divulges novel FXR agonists
Read More
Boehringer Ingelheim and Vanderbilt University expand cancer collaboration
Read More
New IDO1 inhibitors presented by InnoCare Pharma
Read More
Kadimastem cleared to conduct phase I/IIa study of ALS treatment
Read More
Second pivotal phase III study of AbbVie's elagolix meets primary endpoint
Read More
Escalier Biosciences closes series B financing
Read More
Protalix Biotherapeutics' OPRX-106 produces clinical response in study in ulcerative colitis
Read More
FDA accepts sBLA for Keytruda in advanced cervical cancer with priority review
Read More
Eight-week grazoprevir/elbasvir treatment shown effective against HCV infection
Read More
Phanes partners with Crown Bioscience to advance oncology drug discovery pipeline
Read More